Please login to the form below

Not currently logged in

Meda appoints Maria Carell regional director for the US

She joins the Swedish speciality pharma company with management experience from Novartis, Actavis and Q-Med

Swedish speciality pharma company Meda has appointed Maria Carell to a senior management position at its US operations.

She has sat on the firm's board for almost a year and will now take up the role of regional director for the US as Meda waits for a decision from the Food and Drug Administration (FDA) on its rhinitis treatment Dymista.

The US regulator is due to decide in early May on Dymista (azelastine hydrochloride and fluticasone propionate), a nasal spray formulation for patients 12 years and older with seasonal allergic rhinitis.

"Maria Carell will be an important addition to the team that prepares the launch of Dymista in the US", said Anders Lönner, Meda's CEO.

She joins Meda with extensive experience in the health care sector, including management positions at Novartis, generics company Actavis and medical device firm Q-Med.

Following Carell's appointment to the US regional role she has declined re-election to Meda's board.

18th April 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

‘Less Is More: Making Patient-Centered Digital Communication a Reality’
Letizia Affinito writes on the Gower Publishing blog....
The Seven Cs Of Cross-Functional Brand Planning
As more and more organisations have moved to cross-functional and cross-regional involvement in the development of their strategic and operational brand plans, the result has been greater engagement and alignment,...
2015/16 Pharmaceutical Titles
Browse our latest interactive Pharmaceutical and Healthcare catalogue...